Pfizer Inc, has released promising top-line data for its Abrysvo vaccine, demonstrating high efficacy against respiratory syncytial virus (RSV) in adults aged 60 and older. These findings from the Phase 3 clinical trial hold significant implications for infection control personnel working to combat RSV infections, especially in vulnerable populations.
Pfizer logo in New York, NY
(Adobe Stock 432350550 by Kathy images)
Pfizer Inc, has unveiled results from its Phase 3 clinical trial of the Abrysvo vaccine, showcasing robust efficacy against respiratory syncytial virus (RSV) in adults aged 60 and older. For infection control personnel at the forefront of managing infectious diseases, these insights offer valuable perspectives on RSV prevention strategies and the evolving landscape of vaccine development.
“Pfizer has announced efficacy and safety data on their new RSV vaccine, Abrysvo, effective in older adults and infants, two vulnerable populations,” said Sharon Ward-Fore, winner of the Infection Control Today®’s (ICT®’s) 2023 Educator of the Year Award told ICT.
“Pfizer is the only manufacturer of an RSV vaccine. RSV causes between 60,000 to 160,000 hospitalizations and up to 13,000 deaths in people over 60 years old. This vaccine is bivalent, so effective against all RSV lower respiratory tract subgroups. This is good news and another vaccine in our prevention arsenal.”
“Pfizer is the only manufacturer of an RSV vaccine. RSV causes between 60,000 to 160,000 hospitalizations and up to 13,000 deaths in people over 60 years old. This vaccine is bivalent, so effective against all RSV lower respiratory tract subgroups. This is good news and another vaccine in our prevention arsenal.”
The Phase 3 trial, known as RENOIR (RSV vaccine Efficacy study iN Older adults Immunized against RSV disease), revealed a notable vaccine efficacy of 77.8% (95.0% CI: 51.4, 91.1) against RSV-associated lower respiratory tract disease (LRTD) with 3 or more symptoms after the second season. This follows an initial vaccine efficacy of 88.9% (95.0% CI: 53.6%, 98.7%) after the first season, indicating durable protection against RSV.
Furthermore, the data showed consistent efficacy against both RSV A and RSV B subtypes, with vaccine efficacy rates of greater than or equal to 80% for LRTD with 3 or more symptoms. Even against less severe LRTD, defined by 2 or more symptoms, the vaccine-maintained efficacy from 65.1% (95.0% CI: 35.9%, 82.0%) after the first season to 55.7% (95.0% CI: 34.7%, 70.4%) after the second season. Overall, the vaccine demonstrated an efficacy of 81.5% (95.0% CI: 63.3, 91.6) against RSV-associated LRTD with 3 or more symptoms across both seasons.
Importantly, the safety profile of Abrysvo remained favorable, with no new adverse events reported beyond those observed in the first RSV season. These findings provide crucial data for infection preventionists and epidemiologists as they evaluate the potential role of Abrysvo in their RSV prevention strategies.
Annaliesa Anderson, PhD, senior vice president and chief scientific officer of Vaccine Research and Development at Pfizer, expressed optimism about the results in the press release, stating, “We are encouraged by the level of protection that we observed after 2 full RSV seasons for Abrysvo. This data underscores the potential benefit of a bivalent vaccine offering broad and durable protection against both RSV A and RSV B.”
Abrysvo received FDA approval in May 2023 for the prevention of LRTD caused by RSV in individuals aged 60 and older. It was also approved for maternal immunization to protect infants from birth up to 6 months of age. These regulatory milestones, coupled with the strong efficacy data, highlight the potential of Abrysvo in preventing RSV-related morbidity and mortality.
The Abrysvo vaccine is indicated for the prevention of LRTD caused by RSV in people aged 60 years and older, as well as for pregnant individuals at 32 through 36 weeks gestational age to prevent LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age.
Pfizer intends to submit these data to regulatory authorities and vaccine technical committees, paving the way for further discussions on the vaccine's role in RSV prevention strategies. As infection control personnel continue their efforts to mitigate infectious disease risks, the Abrysvo vaccine emerges as a promising addition to their arsenal of preventive measures.
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.